Summit Corporation plc
("Summit" or "the Company")
NOTICE OF ANNUAL GENERAL MEETING
Oxford, UK, 19 May 2010, Summit (AIM: SUMM), a leading UK drug discovery company
with a portfolio of partnered drug programmes and a proprietary Seglin(TM)
technology platform, announces that its Annual Report and Accounts for the year
ended 31 January 2010 ('Annual Report') together with the Notice of Annual
General Meeting ('AGM') have been posted to shareholders. Copies of the Annual
Report and Notice of AGM will also be available on the Company's
The AGM will be held at 10:00am on Thursday, 17 June 2010 at The Milton Park
Innovation Centre, 99 Milton Park, Abingdon, Oxfordshire, OX14 4RY.
- END -
For more information, please contact:
Steven Lee, PhD
Richard Pye, PhD Tel: +44 (0)1235 443939
Singer Capital Markets (Nominated
Shaun Dobson / Claes Spång Tel: +44 (0)20 3205 7500
Tarquin Edwards Tel: +44 (0)7879 458 364
Summit is an Oxford, UK based drug discovery company with a portfolio of partner
funded drug programmes and an innovative technology platform called Seglins(TM)
for the discovery of new medicines.
Summit's partnered drug programmes require no further investment from the
Company but have contractual, success-based milestones potentially worth in
excess of $160 million and sales royalties rising to a low teen percentage.
Partners include leading orphan drug specialist BioMarin Pharmaceuticals
(Duchenne Muscular Dystrophy programme) and the Wellcome Trust (C. difficile
Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches. Summit's
internal research is currently focussed in the high value therapy areas of type
II diabetes and infectious diseases and the Company will further exploit the
technology's wider potential through strategic alliances.
Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM. Further information is available atwww.summitplc.com